Welcome to our dedicated page for Know Labs news (Ticker: KNW), a resource for investors and traders seeking the latest updates and insights on Know Labs stock.
The news archive for Know Labs, Inc. (historically NYSE American: KNW) captures the company’s evolution from a developer of radio frequency dielectric spectroscopy (RFDS) technology for non‑invasive diagnostics to its later transition under the USBC, Inc. name and USBC ticker. Company news releases describe how its RFDS platform directs electromagnetic energy through substances or materials to capture unique molecular signatures, supporting applications such as non‑invasive glucose monitoring and contactless pH measurement.
Readers can review announcements on technology milestones, including laboratory research showing that the company’s RFDS sensor can detect pH changes in real time without direct contact with a liquid, and updates on efforts to advance a non‑invasive blood glucose monitor toward potential FDA clearance. News items also discuss the launch and objectives of Know Labs Technology Licensing (KTL), the division that licenses RFDS technology and the proprietary e‑RFDS© digital watermark to corporations, universities, and research institutions.
The KNW news history further documents significant corporate and capital markets events. These include the 1‑for‑40 reverse stock split effective February 19, 2025, the temporary move to trading on the OTC Pink Market under KNWN while appealing NYSE American delisting proceedings, and subsequent financing and governance developments. Later releases cover the Securities Purchase Agreement with Goldeneye 1995 LLC, the resulting change in control, shareholder approvals to increase authorized common stock and amend the equity incentive plan, and the eventual change of corporate name to USBC, Inc. and trading symbol to USBC.
By browsing this news feed, investors and researchers can trace how Know Labs combined RFDS‑based diagnostic research and licensing with a later strategy that includes a Bitcoin treasury approach and the development of the USBC token, as outlined in joint announcements with Greg Kidd and related SEC filings.
Know Labs, Inc. (KNW) has successfully completed its underwritten public offering, closing on 4,140,000 shares of Common Stock at $2.00 per share, generating approximately $8.28 million in gross proceeds. The offering included the underwriter’s option for an additional 540,000 shares. Trading for KNW stock commenced on the NYSE American on September 16, 2022. Boustead Securities, LLC served as the sole underwriter for the transaction.
Know Labs, Inc. (NYSE American: KNW) has announced a public offering of 3,600,000 shares at $2.00 per share, aiming to raise approximately $7.2 million before discounts and expenses. The offering is set to close on or around September 20, 2022, following a trading debut on September 16, 2022. Boustead Securities, LLC is acting as the sole underwriter. The company’s advanced Bio-RFID technology aims to revolutionize non-invasive medical diagnostics, starting with a glucose monitoring product pending FDA clearance.